OBJECTIVE: To determine whether obesity and insulin resistance associate with changes in the protein content of high-density lipoprotein (HDL) in 2 different groups of men by using targeted proteomics. METHODS AND RESULTS: Insulin resistance and obesity are hallmarks of type 2 diabetes mellitus and the metabolic syndrome, which confer an increased risk of cardiovascular disease. Recent studies suggest that the protein cargo of HDL makes important contributions to the lipoprotein's cardioprotective effects. In a discovery study, we used isotope dilution mass spectrometry to quantify the relative concentrations of 5 proteins previously implicated in HDL's cardioprotective effects in 3 groups of healthy subjects: lean insulin-sensitive, lean insulin-resistant, and obese insulin-resistant individuals. We validated our findings in a different group of subjects. The clusterin concentration in HDL strongly and negatively associated with insulin resistance and body mass index in both populations. HDL clusterin levels were lower in subjects with low HDL and high triglycerides, key components of the metabolic syndrome. There was an inverse correlation between clusterin levels in HDL and very-low-density lipoprotein/low-density lipoprotein. CONCLUSIONS: Clusterin levels in HDL are lower in men with reduced insulin sensitivity, higher body mass index, and an unfavorable lipid profile. Our observations raise the possibility that clusterin depletion contributes to the loss of HDL's cardioprotective properties.
OBJECTIVE: To determine whether obesity and insulin resistance associate with changes in the protein content of high-density lipoprotein (HDL) in 2 different groups of men by using targeted proteomics. METHODS AND RESULTS:Insulin resistance and obesity are hallmarks of type 2 diabetes mellitus and the metabolic syndrome, which confer an increased risk of cardiovascular disease. Recent studies suggest that the protein cargo of HDL makes important contributions to the lipoprotein's cardioprotective effects. In a discovery study, we used isotope dilution mass spectrometry to quantify the relative concentrations of 5 proteins previously implicated in HDL's cardioprotective effects in 3 groups of healthy subjects: lean insulin-sensitive, lean insulin-resistant, and obese insulin-resistant individuals. We validated our findings in a different group of subjects. The clusterin concentration in HDL strongly and negatively associated with insulin resistance and body mass index in both populations. HDL clusterin levels were lower in subjects with low HDL and high triglycerides, key components of the metabolic syndrome. There was an inverse correlation between clusterin levels in HDL and very-low-density lipoprotein/low-density lipoprotein. CONCLUSIONS:Clusterin levels in HDL are lower in men with reduced insulin sensitivity, higher body mass index, and an unfavorable lipid profile. Our observations raise the possibility that clusterin depletion contributes to the loss of HDL's cardioprotective properties.
Authors: Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke Journal: J Clin Invest Date: 2007-03 Impact factor: 14.808
Authors: Miriam Cnop; Melinda J Landchild; Josep Vidal; Peter J Havel; Negar G Knowles; Darcy R Carr; Feng Wang; Rebecca L Hull; Edward J Boyko; Barbara M Retzlaff; Carolyn E Walden; Robert H Knopp; Steven E Kahn Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: Yara Banz; Otto M Hess; Simon C Robson; Eva Csizmadia; Daniel Mettler; Pascal Meier; André Haeberli; Sidney Shaw; Richard A Smith; Robert Rieben Journal: Cardiovasc Res Date: 2007-08-02 Impact factor: 10.787
Authors: Erdenechimeg Shagdarsuren; Kiril Bidzhekov; Yassin Djalali-Talab; Elisa A Liehn; Mihail Hristov; Robert A Matthijsen; Wim A Buurman; Alma Zernecke; Christian Weber Journal: Circulation Date: 2007-12-10 Impact factor: 29.690
Authors: Chiara Buono; Carolyn E Come; Joseph L Witztum; Graham F Maguire; Philip W Connelly; Michael Carroll; Andrew H Lichtman Journal: Circulation Date: 2002-06-25 Impact factor: 29.690
Authors: Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle Journal: J Proteome Res Date: 2015-03-13 Impact factor: 4.466
Authors: Katya B Rubinow; Chongren Tang; Andrew N Hoofnagle; Christin N Snyder; John K Amory; Jay W Heinecke; Stephanie T Page Journal: Steroids Date: 2012-01-15 Impact factor: 2.668
Authors: Konstantinos N Aronis; Maria T Vamvini; John P Chamberland; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2011-09-07 Impact factor: 5.958
Authors: Sang Soo Kim; Sang Heon Song; Jong Ho Kim; Yun Kyung Jeon; Bo Hyun Kim; Min-Cheol Kang; Sung Wan Chun; Soo Hyun Hong; Michelle Chung; Yong Ki Kim; In Joo Kim; Young-Bum Kim Journal: Clin Endocrinol (Oxf) Date: 2017-05-22 Impact factor: 3.478
Authors: A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739
Authors: Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb Journal: Nat Rev Cardiol Date: 2015-09-01 Impact factor: 32.419
Authors: Ji A Seo; Min-Cheol Kang; Theodore P Ciaraldi; Sang Soo Kim; Kyong Soo Park; Charles Choe; Won Min Hwang; Dong Mee Lim; Olivia Farr; Christos Mantzoros; Robert R Henry; Young-Bum Kim Journal: Metabolism Date: 2017-10-03 Impact factor: 8.694